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Although glucocorticoids are frequently administered to patients with hormone refractory prostate cancer, their therapeutic effectiveness is
limited by the development of glucocorticoid resistance. The molecular mechanisms of glucocorticoid resistance are unknown but are believed to
involve neuropeptide growth factors and cytokines. We examined the functional interaction between bombesin and dexamethasone in PC-3 cells
and found that bombesin could act as a survival factor by interfering with dexamethasone-mediated growth inhibition. Because glucocorticoids
exert their effects through glucocorticoid receptors (GRs), we measured the expression of GRα and GRβ isoforms in the presence of bombesin.
Western blotting and real time PCR revealed bombesin induced expression of GRβ, but not GRα. Because GR isoforms are generated by
alternative splicing of a common GR gene, we examined the expression of serine-arginine (SR) proteins involved in alternative splicing, and found
that the expression of SRp30 was induced by bombesin in PC-3 cells. To characterize the role of SRp30 in splicing of GR isoforms, siRNAs
specific to various SRp30 isoforms were transfected into PC-3 cells. We found that suppression of SRp30c expression by siRNA specifically
antagonized bombesin's effect on glucocorticoid-mediated inhibition of PC cells, suggesting that bombesin-induced expression of SRp30c affects
GR pre-mRNA splicing, leading to increased GRβ expression and contributing to glucocorticoid resistance in PC cells.
Published by Elsevier B.V.Keywords: Glucocorticoids; Glucocorticoid receptors; SRp30 proteins; Bombesin; Neuropeptides; Prostate cancer1. Introduction
Glucocorticoid (GC) monotherapy in patients with hormone
refractory prostate cancer is of limited utility, resulting in
response rates of approximately 20% [1–3]. Such responses,
characterized by decreases in PSA, tumor size, and/or pain are
typically of short duration [4–8] due to the development of GC
resistance. The molecular mechanisms governing GC resistance
are unknown.⁎ Corresponding author. Tel.: +1 212 746 5028; fax: +1 212 746 8941.
E-mail address: rshen@med.cornell.edu (R. Shen).
0167-4889/$ - see front matter. Published by Elsevier B.V.
doi:10.1016/j.bbamcr.2007.04.016Glucocorticoids bind glucocorticoid receptors (GR) and
subsequently exert their anti-tumor effects by facilitating
signaling pathways leading to apoptosis or necrosis [9–12].
Human glucocorticoid receptors (hGR), members of the nuclear
receptor superfamily, undergo pre-mRNA alternative splicing in
exon 9 resulting in two highly homologous receptor isoforms,
hGRα and hGRβ. These isoforms are identical through amino
acid 727 but differences at their carboxyl-termini account for
their differing functions. While GRα functions as a ligand-
dependent transcription factor, hGRβ inhibits the transcrip-
tional activity of hGRα in a dose dependent manner [13,14].
Splicing in eukaryotes occurs in the spliceosome, comprising
serine-arginine-rich proteins (SR proteins) and small nuclear
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can positively or negatively regulate spliceosome function
depending on their precise location, composition and state of
modification. Variation in the relative concentrations of splicing
factors can simultaneously affect splice-site choice in multiple
pre-mRNAs. Changes in levels of various SR proteins occur
during tumor progression and correlate with changes in the
mRNAs produced by a specific spliceosome [17,18]. One such
SR protein, SRp30 is ubiquitously expressed as multiple
subspecies (SRp30 a–c) and exhibits structural similarities
with alternative splicing factor SF2/ASF (SRp30a) and SC35
(SRp30b). The SRp30c subspecies may directly contact RNA
via two independent RNA recognition motifs that are linked by
a glycine-hinge, also binds to CE9 (an intronal element that can
repress the 3′ splice site of exon 8 in the hnRNPA1 pre-mRNA)
and acts as a repressor of 3′ splice site utilization [19]. SRp30c
protein also directs GR splicing in neutrophils [20].
Bombesin is a fourteen amino acid neuropeptide. Bombesin
and other members of the bombesin-like polypeptide family are
ligands for G protein-coupled receptors (GPCRs) and can
influence multiple signaling pathways conducive to PC pro-
gression [21,22]. Bombesin can induce FAK phosphorylation,
ligand-independent phosphorylation of the IGF-1 receptor and
Akt, and rapid PKCδ degradation [23–25]. More recently we
have shown that bombesin augments both androgen receptor
(AR) mediated transcription [26], and histone acetyltransferase
activity of AR coactivator p300 [27]. Furthermore, bombesin
can augment the expression of the angiogenic factors
interleukin-8 (IL-8) and vascular endothelial growth factor
(VEGF) [28], and induce resistance to etoposide-induced
apoptosis [29]. Together these studies suggest that bombesin
contributes to PC progression.
In the present study, we report a novel role for bombesin in
regulating the pre-mRNA splicing of GR isoforms. Our results
demonstrate that bombesin can induce the expression of
splicing factor SRp30c which leads to an increase of GRβ
expression, thereby diminishing the GC responsiveness of PC
cells.
2. Materials and methods
2.1. Materials and chemicals
Bombesin and dexamethasone (DEX) were purchased from Sigma
Biotechnology Inc. Small interference (si) RNA of non-targeting siRNA and
siRNAs against the a, b and c subspecies of SRp30 proteins were purchased
from Dharmacon Inc. (Chicago, IL). Anti-GR α antibody was purchased from
Santa Cruz Biotechnology Inc., (Santa Cruz, CA); and anti-GR β from Affinity
Bioreagents (Golden, CO). Anti-actin antibody was obtained from Sigma-
Aldrich Inc. (Saint Louis, MO). Antibodies against SR proteins were purchased
from ATCC, Inc. The plasmid pSRp30c-c2 (expressing a fusion protein GFP-
SRp30c) was kindly provided by Dr. S. Stamm, (Institute of Biochemistry,
Erlangen, Germany).
2.2. Cell culture and growth inhibitory assays
PC-3 cells were maintained in RPMI1640 supplemented with 2 mM
glutamine, 1% nonessential amino acids, 100 U/ml streptomyocin and
penicillin, and 10% FCS. This media was replaced with RPMI 1640 containing
5% charcoal stripped serum (CS) prior to various treatments. Growth assayswere performed as described [23,24]. All growth assays were performed in
triplicate on three separate occasions with similar results.
2.3. Western blotting
Cells were lysed in RIPA buffer [10 mM Tris–HCl (pH 7.4), 150 mM NaCl,
1% Triton X-100, 5 mM EDTA, 1% sodium deoxycholate, 0.1% SDS, 1.2%
aprotinin, 5 μM leupeptin, 4 μM antipain, 1 mM phenylmethylsulfonyl fluoride
and 0.1 mM Na3VO4]. Twenty to fifty micrograms of protein from each sample
was suspended in 2× laemmli sample buffer, resolved on a 7 or 10% SDS-
PAGE, and transferred to a nitrocellulose membrane. Western blotting was
performed as described previously [23,24] using diluted primary and secondary
antibodies. All Western blot experiments were performed at least twice using
different cell lysates with similar results.
2.4. Transfection, CAT assays and application of siRNAs
Transfection of CAT reporter vectors was conducted using Lipofectamine
(Invitrogen Inc.) as previously described [27,30]. The experiments were
performed in duplicate or triplicate on at least three separate occasions and CAT
activities expressed reported relative to untreated controls.
2.5. Real-time quantitative RT-PCR analysis
PCR was performed using the ABI 7000 system and SYBR green I dye
(ABI). Thermocycling was carried out in a final volume of 20 μl, containing 2 μl
of cDNA sample, 3.5 mM MgCl2, 0.1 μM primers and 10 μl SYBR green I
master mix. After a 10 min initial denaturation at 95 °C, the 50-cycle run
consisted of a 15-s denaturation step at 95 °C and an annealing and extension
step at 60 °C for 1 min. To avoid amplification of genomic DNA, the forward
and reverse primers were designed spanning different exons. The mean of three
repeated PCR values was used in the statistical analysis. Results were
normalized to β-actin by dividing the individual RT-PCR values by the mean
of three repeated β-actin test values of the representative samples to reduce
variability between RNA amounts introduced into the RT-PCR reactions. To
distinguish the specific PCR products from non-specific products and primer
dimers, the melting curve was determined as described previously [31]. Samples
were also analyzed by agarose gel electrophoresis to verify that the amplified
products exhibited their calculated molecular weights.
2.6. Statistics
The student unpaired t-test (Prism 4 for Windows, GraphPad Software Inc.
CA) was used for calculation of P values.
3. Results
3.1. Bombesin interferes with GC induced growth inhibition in
PC-3 cells
In vitro studies demonstrate an antiproliferative effect of
GCs on human PC cells [32]. To examine whether bombesin, a
neuropeptide acting as a survival factor, interferes with GC-
induced PC cell growth inhibition, we first performed cell
growth assays in the presence of bombesin and DEX in PC-3
cells. Fig. 1A demonstrates that treatment of PC-3 cells with
DEX concentrations of 0.1, 1, 10 nM and 100 nM led to
growth inhibition of 60%, 66%, 60% and 52%, respectively,
compared to untreated controls. Treatment with 50 nM
bombesin+10 nM DEX (shaded bar vs. open bar in lane 10,
P=0.011) and 50 nM bombesin+100 nM DEX (shaded bar
vs. open bar, P=0.013) significantly reduced GC-induced
growth inhibition.
Fig. 1. Bombesin interferes with GC induced growth inhibition in PC-3 cells.
(A) PC-3 cells were grown in RPMI1640 containing 5% CS. Cells were treated
daily with increasing concentrations of Dexamethasone (DEX), either in the
absence (white bars) or in the presence of 50 nM bombesin (BBS) (dark bars).
After 4 days, cells were harvested and counted in a hemocytometer. Cell
viability was determined by dye exclusion after Trypan Blue staining. Error bars
indicated. Pb0.02. In lane 0, the open bar denotes vehicle treatment (equal
amount of ethanol and distilled water) for GC and bombesin and the shaded bar
the vehicle treatment (equal amount of ethanol) plus bombesin alone. (B) GRE-
tkCAT, a plasmid with glucocorticoid receptor responsive element (GRE) in
front of thymidine kinase (tk) promoter and CAT reporter gene, was transfected
into PC-3 cells by lipofectamine method. Twenty-four hours after transfection,
medium were replaced by RPMI1640 containing 5% CS and treated without
(CON) (lane 1) or with 50 nM bombesin alone (BOM) (lane 2), various
concentrations of DEX (1 nM, 10 nM and 50 nM) (lanes 3, 4, 5) and in
combination with 50 nM bombesin (1 nM GC+B, 10 nM GC+B and 50 nM
GC+B) (lanes 6, 7 and 8) for 18 h. Measurements of CATactivities were carried
out and relative CAT activities were calculated by comparing the values of
various treatments vs. control. Error bar indicated. Pb0.01.
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if bombesin countered GC-induced growth inhibition by
interfering with GR activity, we determined the effects of
bombesin on CAT activities in PC-3 cells transiently transfected
with the plasmid GRE-tk-CAT, containing a glucocorticoid
responsive element (GRE) upstream of the thymidine kinase
(tk) promoter. As shown in Fig. 1B, treatment with 50 nM
bombesin and DEX led to decreased CAT activities of 40%
(1 nM DEX), 38% (10 nM DEX) and 30% (50 nM DEX)
compared to GC treatments alone.
3.2. Bombesin augments mRNA and protein levels of GRβ
Glucocorticoid signaling is mediated by both the active
isoform GRα and dominant negative isoform GRβ. The ratio
between GRα and GRβ levels determines GC-induced reporter
gene expression in vitro [33]. To examine whether the
regulatory effects of bombesin on GC-induced CAT activitiesresult from altered splicing of GR, we measured the effect of
bombesin on GRα and GRβ mRNA and protein levels. Fig. 2B
showed that following bombesin treatment, GRβ mRNA
increased 3.2 (lanes 4h vs. 0h, P=0.009) and 1.7 fold relative
to control (lanes 18h vs. 0h, P=0.008) at 4 and 18 h,
respectively, whereas little change was detected in GRα
mRNAs (1.3 and 0.8 fold relative to the control, Lanes 4h vs.
0h, P=0.52, and lanes 18 h vs. 0 h, P=0.62, respectively). The
increase in GRβ mRNA paralleled an increase in GRβ protein
at 18 h (Fig. 2C). The increased expression of GRβ mRNA and
protein suggested that bombesin treatment specifically altered
the splicing of the GRβ gene.
3.3. Induction of SRp30 proteins by bombesin
SR proteins are major components of the spliceosome and
play a key role in pre-mRNA splicing of steroid receptors and
other proteins [34]. We therefore assessed whether bombesin
altered SR protein expression in PC-3 cells. Western blot
analysis using the antibody (16H3, ATCC, CRL-2385) which
recognizes SRp20, SRp30, SRp40, SRp55 and SRp75 proteins
[34] revealed that SRp30 protein expression but not that of other
SR proteins was augmented at 18 h following treatment with
50 nM bombesin (Fig. 3, lanes bombesin vs. control). A kinetic
analysis showed that the expression of SRp30 protein was
induced by bombesin at 18 h. These data indicate that SRp30,
like GRβ, is induced by bombesin treatment of PC-3 cells.
3.4. SRp30c is responsible for aberrant GRβ splicing induced
by bombesin
Xu, et al. reported that SRp30 protein directs alternative
splicing of GR pre-mRNA to GRβ in neutrophils [20]. The
expression of SRp30 induced by bombesin suggests SRp30
may be responsible for the aberrant splicing of GR isoforms by
bombesin. SRp30 comprises three subspecies: SRp30a (SF2/
ASF), SRp30b (SC35) and SRp30c. To identify the subspecies
potentially responsible for the altered splicing of GRβ, we
conducted quantitative real time reverse transcriptase PCR,
quantifying their relative expression in PC-3 cells. All sub-
species were detected with SRP30c being the most abundant
(Fig. 4A). This expression pattern differed markedly from that
observed in neutrophils, where SRp30c was the only detectable
subspecies [20].
To assess the relative contribution of the various SRp30
subspecies in modulating GR splicing in PC-3 cells, we
introduced siRNAs of SRp30a, SRp30b and SRp30c into PC-
3 cells to suppress their expression (Fig. 4B–E), and assessed
GR splicing following bombesin treatment. Alternative splicing
of GR pre-mRNA to GRβ was not affected with treatment of
non-targeting siRNA, nor was it affected with siRNAs
specifically targeting SRp30a and b proteins (panels GRβ,
Fig. 4B–D). However, targeting of SRp30c with a specific
siRNA resulted in a significant reduction in GRβ production at
18 h after transfection (panel GRβ, Fig. 4E), whereas GRα
production was not affected (panels GRα, Fig. 4B–E). These
data suggest that in the presence of bombesin, SRp30c mediates
Fig. 2. Bombesin induced GRβ on both protein and RNA levels in PC-3 cells. (A) Schematic illustrating that alternative splicing of exons 9α and 9β results in two
isoforms (GRα and GRβ) from GR gene [46]. (B) Message RNA levels of GRα and GRβ in the presence of 50 nM bombesin. The RNAs prepared from PC-3 cells
with bombesin treatment at various time points (0, 4 h and 18 h) were subjected to real time RT-PCRmeasurement. PCR was performed using primers specific to GR α
and GRβ and normalized by that of β-actin. (C) Western analysis of GR α and β proteins in the presence of bombesin. PC-3 cells were treated with 50 nM bombesin at
0, 4 and 18 h (lanes C, 4 and 18). Blots were detected with anti-GRα, anti-GRβ and anti β-actin antibodies.
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increased generation of GRβ mRNA.
3.5. SRp30c affects bombesin-mediated interference of GC
action in MMTV-CAT
To confirm the functional significance of SRp30c expression
in the GR pathway, we next tested the SRp30 isoform siRNAs
on expression of the hormone-responsive MMTV promoter
using PC-3 cells transfected with a plasmid containing an
MMTV promoter upstream of a CAT reporter gene. As shown
in Fig. 5A, DEX-induced CATactivities were reduced to 42% in
the presence of 50 nM bombesin compared to treatment with
DEX alone (lanes 4 vs. 3) similar to that observed for the GRE-
tk-CAT vector (as described in Fig. 1A). While siRNAs to
SRp30a and b did not affect CAT activities (38% and 45%, Fig.
5A, lanes 5 and 6 vs. 3), transfection of SRp30c siRNA
effectively abolished bombesin inhibition of MMTV-CAT
activity induced by DEX (Fig. 5A, lanes 7 vs. 3). Prostate
cancer cells transfected with the vector pSRp30c-c2 over-
expressed SRp30c as a GFP fusion protein (Fig. 5B) andexhibited lower CAT activities in both GC and bombesin+GC
treated cells (Fig. 5C), when compared to that of control vector
expressing GFP (45%, lane 7 vs. lane 3, P=0.009, and 44%,
lane 8 vs. lane 4, P=0.008). These results suggest that the
overexpression of SRp30c led to elevated GRβ expression and
resulted in decreased GR reporter activity. In contrast, no
SRP30c dependent changes in CAT activity were detected
between treated and untreated cells (Fig. 5C, lanes 5 vs. 1 and
lanes 6 vs. 2). Taken together, the data demonstrate that
elimination (or enhancement) of SRp30c expression can
regulate the splicing of GRβ to antagonize (or augment) the
effect of bombesin on GC action.
3.6. Suppression of SRp30c expression eliminates bombesin's
antagonism of GC action on PC-3 cell growth
The above results demonstrate that SRp30c plays a key role
on bombesin-mediated interference of GC induced CAT
activities in vitro. To verify whether this is the case in vivo,
we examined the effects of siRNA of SRp30c on growth of PC-
3 cells in the presence of GC and bombesin. As shown in Fig. 6,
Fig. 4. Suppression of GRβ expression by siRNAs of SRp30 proteins. (A) Real time P
Message RNA levels of SRp30 a, b and c subspecies were measured by real time P
(B–E) The effects of siRNAs of a, b and c subspecies of SRp30 proteins and non-
RNAs of a, b and c subspecies of SRp30 protein and non-targeting siRNA (Dharma
hours after transfection cells were treated with or without 50 nM bombesin. Cell l
antibodies of GRα, GRβ, SR proteins and β actin respectively.
Fig. 3. Induction of SRp30 protein by bombesin in PC-3 cells. (A) PC-3 cells
cultured in RPMI 1640 containing 5% CS medium were treated without (lane
Control) or with 50 nM bombesin (lane Bombesin) and IL-8 (0.25 μg/ml,
positive control) (lane IL-8). Western blots were probed with anti-SR proteins
and anti-actin antibodies. Arrows show SRp30 and another SR protein (SRp40).
(B) Time course of SRp30 protein induction by bombesin in PC-3 cells. Cells
treated with 50 nM bombesin at various times (0, 1 h, 4 h and 18 h) were lysed
and subjected to Western analysis. Blots were probed with anti-SR proteins and
anti-β-actin antibodies.
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PC-3 cells (lanes 1–4), inclusion of 50 nM bombesin together
with 100 nM DEX resulted in a 22% increase in cell number
(lanes 4 vs. 3, P=0.0135) relative to treatment with 100 nM
DEX alone. When siRNA directed against SRp30c was
transfected, the increase in cell number following bombesin
treatment was significantly reduced to 16% (lanes 5 vs. 4,
P=0.0374), showing that suppression of SRp30c expression
using a specific siRNA attenuates bombesin's antagonism of
GC action in PC cells. Together these data indicate that SRp30c
subspecies plays an important role in bombesin-mediated
survival effect in the presence of GC in PC cells.
4. Discussion
GCs have been used in clinical oncology for more than three
decades and have been an integral part of endocrine treatment
for advanced PC. However the molecular mechanisms under-
lying the development of GC resistance are poorly understood.
In this study we report that the survival factor bombesin can
reverse GC action (Fig. 7). We demonstrate that: (1) bombesin
interferes with the inhibitory effects of GCs on proliferation of
PC cells; (2) bombesin causes an up-regulation of protein andCR showing expression of a b and c subspecies of SRp30 proteins in PC-3 cells.
CR as described in Materials and methods. Data were expressed as mean±S.E.
targeting siRNA on expressions of GRα and GRβ proteins. Small interference
co Inc.) were transfected into PC-3 cells by lipofectamine method. Twenty-four
ysates were resolved on 4–20% SDS PAGE and the blots were detected with
Fig. 6. The effect of SRp30c siRNA on growth of PC-3 cells in the presence of
GC and bombesin. SiRNAs of non-targeting (lanes 1–4) or SRp30c protein were
transfected into PC-3 cells. Twenty-four hours later, treatments without (lane 1)
or with 50 nM bombesin (lane 2), 10 nM DEX (lane 3), and 50 nM bombesin+
10 nM DEX (lanes 4 and 5) were carried out and cell growth was measured the
same as described in Fig. 1. Y axis: survival cell numbers. X axis: various
treatments. P values were calculated by ANOVA. Error bars indicated.
Fig. 5. The effects of SRp30c on CAT activities of MMTVCAT in the presence
of bombesin and GC. (A) The effects of siRNAs of SRp30a, SRp30b and
SRp30c on CAT activities of MMTVCAT. PC-3 cells were transfected without
(lanes 1–4) or with siRNAs of SRp30a, SRp30b and SRp30c (lanes 5, 6 and 7).
Twenty-four hours later, treatments without (lane 1) or with 50 nM bombesin
(lane 2), 10 nM DEX (lane 3) and 50 nM bombesin+10 nM DEX (lanes 4–7)
were performed and the resultant CAT activities were measured as described
before. (B) GFP fluorescence of transfected pSRp30c-c2 PC3 demonstrating the
overexpression of GFP-SRp30c. (C) The effect of overexpression of SRp30c on
CAT activities. Lanes 1–4 were mock-transfected cells and lanes 5–8 were cells
transfected with pSRp30c-c2. Treatments without (lanes 1 and 5) or with 50 nM
bombesin (lanes 2 and 6), 10 nM DEX (lanes 3 and 7) and 50 nM bombesin+
10 nM DEX (lanes 4 and 8) were performed and CAT activities measured.
Fig. 7. Schematic illustrating the role of bombesin in mediating GC resistance in
PC cells. During androgen withdrawal, up-regulation of SRp30c protein by
bombesin leads to aberrant splicing of GR gene and the increased level of GRβ
protein, which in turn confers resistance to GC in PC cells.
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of SRp30 protein; and 4) bombesin-induced alternative splicing
of GR can be reversed by suppressing the SRp30c subspecies.Our data confirm and extend the finding that neuropeptides
can antagonize the action of glucocorticoids on PC cells.
Hormones or cytokines either employed in prostate cancer
endocrine therapy or elevated in prostate cancer have been
reported to function as GR antagonists. Krishnan, et al.
demonstrated that estrogen, E2 had an anti-GC action in
human breast cancer cells [35]. Autocrine or paracrine secretion
of lymphokines with subsequent activation of survival path-
ways has been implicated in GC resistance in numerous systems
[36]. Recently, the proinflammatory cytokine, IL-1α, was
shown to antagonize DEX action in mouse L929 cells [37].
Our results suggest that bombesin modulates GR-mediated
1093J. Zhu et al. / Biochimica et Biophysica Acta 1773 (2007) 1087–1094transactivation by altering expression of GRs. GRs are reported
to be present in several human prostate cancer cell lines. GC
activity is lacking in GR-negative LNCaP cells, but clearly
present in GR-positive PC-3 and DU-145 cells [38].
Several studies report GRβ protein is capable of exhibiting a
dominant negative function [32,39]. The preferential increase in
the beta isoform of the human GR has also been seen in several
disease states resistant to GC therapy. Recently, increased GRβ
levels have been reported in human T cells localized to airways,
peripheral blood mononuclear cells, and in tuberculin-induced
inflammatory lesions in GC-insensitive asthmatics [40]. In
another report, higher levels of GRβ were found in 10 of 12
patients with GC-resistant colitis [41]. The cytokines TNF-α
and IL-1 were reported to interfere with GC-induced apoptosis
by changing the GRα and GRβ ratio [42,43]. Additionally,
isolated peripheral blood mononuclear cells, when stimulated
with various superantigens, became insensitive to GC, and this
insensitivity is believed to be the result of increased GRβ [44].
All these studies underscore the strong correlation between the
expression of GRβ and generalized resistance to GC therapy in
human disease states. Our studies are consistent with those
previous observations and also reveal a molecular mechanism
by which GC resistance may be achieved. The mechanisms
could potentially impact multiple GC target genes and interact
with downstream effectors of bombesin as well.
To investigate the aberrant splicing of GRβ, we studied the
expression of splicing factors SR proteins. Specifically, the
SRp30c subspecies leads to increased alternative splicing of
GRβ mRNA and expression in the presence of bombesin.
SRp30c is a repressor of 3′ splice site utilization [19] and has
been found to stimulate alternative splice site selection in CD45
pre-mRNA in leukocytes [45]. A bioinformatics search of the
region covering the sequences responsible for splicing of GR
gene revealed the presence of several exonic splicing enhancers
(ESEs) for SRp30c interaction (data not shown), suggesting that
the augmented expression of SRp30c by bombesin might lead
to the repression of the splicing of exon 9α (or enhancement of
the splicing of exon 9β) to generate a higher level of GRβ.
Our studies demonstrated that SRp30c played the primary
function in regulation of GR splicing both in vitro and in vivo.
Nevertheless, the antagonizing effects of SRp30c siRNA on cell
growth was relatively weak when compared to that in vitro.
Other splicing factors, such as hnRNPs which antagonize the
effects of SR proteins, may play a role in bombesin-mediated
GR splicing in vivo. Recently it has been reported that
transcription may couple with the splicing process. All these
warrant our further studies when considering the mechanisms
underlying bombesin-induced GC resistance.
This study is first to demonstrate neuropeptide antagonism of
GC function by altering GR splicing. Anti-survival factor
therapy aims at neutralizing the protective effect conferred by
the survival factors derived from the local microenvironment.
Since GRβ is intimately involved in GC insensitivity, and GRβ
is dependent on the presence of SRp30c, the pathway involving
SRp30c protein may be an attractive therapeutic target for
restoring GC sensitivity to hormone refractory PC and may
account for patient differences in GC responsiveness. More-over, the ability of neuropeptides to induce GC resistance may
play an important role in other clinical settings such as bone
turnover and the neuroendocrine response to stress.
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